Cardiac Biomarkers Market

Cardiac Biomarkers Market Research, 2034

Cardiac Biomarkers Market is projected to exhibit a Compound Annual Growth Rate (CAGR) of 13.8% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 13.9 billion and is projected to reach USD 58.1 billion by the completion of 2034.

Cardiac biomarkers are compounds released into the bloodstream in response to heart damage or stress. They act as distress signals sent out by the heart. Various enzymes, hormones, and proteins, such as cardiac troponins and creatine kinase (CK), are examples of these biomarkers. Troponin is a key cardiac biomarker for detecting heart attacks, while CK-MB can also indicate heart damage. BNP is often used for diagnosing heart failure, and NT-proBNP serves a similar purpose in monitoring and diagnosing heart failure. These biomarkers play a crucial role in diagnosing heart attacks, assessing the severity of heart failure, tracking the effectiveness of treatments, and screening individuals at high risk. They offer advantages including early detection, high specificity and sensitivity, and treatment recommendations.

Market Highlights

Cardiac Biomarkers Market is anticipated to grow at a robust rate, with projections indicating a 13.8% compound annual growth rate (CAGR) between 2024 and 2034

Cardiac Biomarkers Market is expected to reach USD 58.1 billion during the forecast period. The rising prevalence of heart diseases globally is leading to a higher demand for diagnostic and monitoring tools like cardiac biomarkers. Additionally, with the world's population aging, there is a growing incidence of cardiovascular diseases, highlighting the importance of reliable diagnostic biomarkers. The market is also fueled by the growing understanding of the advantages of early detection and preventive care. Furthermore, the development of improved biomarker testing technologies that are more sensitive and faster is expected to drive market growth. Increased investment in cutting-edge diagnostic technology and personalized healthcare further contributes to the expansion of the market.

Source: Fatpos Global

Cardiac Biomarkers Market Segmentation

Troponin segment is anticipated to lead owing to its high specificity and sensitivity

Cardiac Biomarkers Market is segmented based on Type into Creatine Kinase-MB (CK-MB), Troponin, B-type Natriuretic Peptide (BNP), N-terminal Pro-BNP (NT-proBNP), and Others. The Troponin segment is anticipated to lead the market due to its high specificity and sensitivity. Troponin ensures accurate detection of heart attacks and distinguishes them from other heart conditions. It is widely recognized as the most effective way to diagnose heart attacks and is frequently used in emergency rooms and medical centers. Additionally, troponin levels can be observed soon after heart damage and may remain elevated for several days, enabling timely and accurate detection of myocardial injury, which is crucial for prompt medical treatment and improved patient outcomes. There is also a well-established infrastructure and protocols for troponin testing, ensuring widespread availability and integration into standard practices.

Acute Coronary Syndrome segment will dominate the industry due to its high incidence

Cardiac Biomarkers Market is classified based on Application into Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, and Others. The Acute Coronary Syndrome segment will dominate the industry due to its high incidence. ACS, including heart attacks and unstable angina, is a leading cause of emergency visits and hospital stays, emphasizing the importance of fast and precise diagnosis for prompt treatment. The rise in urbanization and sedentary lifestyles is contributing to the spread of the disease. Rapid diagnosis and intervention in ACS are crucial for better outcomes, highlighting the importance of biomarker testing. Furthermore, biomarkers, particularly troponin, have shown great sensitivity and specificity in identifying myocardial damage related to ACS.

Source: Fatpos Global

Market Dynamics

Growth Drivers

Increasing Incidence of Heart Conditions are Critical to Boosting the Adoption of Cardiac Biomarkers

The rising prevalence of heart conditions is driving substantial growth in the cardiac biomarkers market. This increase in demand for diagnosis and monitoring is fueled by a greater emphasis on early detection and preventive care. There is a growing need for precise diagnostic tools like cardiac biomarkers as cases of acute coronary syndrome, heart attacks, and heart failure continue to rise. These biomarkers play a crucial role in monitoring disease progression and informing treatment decisions. Additionally, ongoing advancements in testing methods are being driven by the need for quick and accurate diagnosis to prevent issues and improve outcomes. Increased investment in advanced diagnostic equipment in the healthcare sector is also contributing to the development of novel tests, further driving market growth

Advancements in Cardiac Biomarker Technologies Will Aid the Market

Market growth is significantly propelled by advances in cardiac biomarker technologies. Improved precision and reliability of novel tests lead to greater detection capabilities, resulting in increased clinical use and regular monitoring. Faster testing procedures lead to quicker outcomes, which are crucial for prompt identification and care, especially in urgent situations. Innovations have also resulted in the identification of new biomarkers, increasing diagnostic options and addressing a broader range of heart conditions. Additionally, incorporating automation and other diagnostic tools into workflows improves efficiency and attracts healthcare providers. These factors enhance diagnosis, efficiency, and personalized care, contributing to the expansion of the cardiac biomarkers market..

Restraints

High Costs of Cardiac Biomarker Tests Can Limit the Growth of the Cardiac Biomarkers Market

High costs of cardiac biomarker tests are a significant barrier to the growth of the cardiac biomarkers market. Financial barriers, especially in low-resource settings or among underinsured patients, limit accessibility and can cause delays in diagnosis and treatment. Additionally, the escalating healthcare costs due to expensive tests strain hospital budgets, leading to a preference for cheaper diagnostic methods. The perceived benefits of these costly tests may not always justify their high expenses, prompting a shift toward more affordable alternatives. Insurance coverage issues also contribute to limited access, as not all policies fully cover advanced tests, leaving patients to bear the costs out of pocket, which significantly restricts market growth.

Recent Developments

• In 2024, Siemens launched the Atellica® BNP test to enhance the precision of heart failure diagnoses.
• In 2024, Cardinal Health dedicated funds towards research for creating novel cardiac biomarkers aimed at detecting heart disease early, with a focus on groundbreaking diagnostic methods.
• In 2023, Abbott created a cardiac biomarker testing system for home use, enabling patients to track their heart health from a distance.
• In 2023, the Elecsys® Troponin T Gen 5 test was launched by Roche, providing better sensitivity for early recognition of heart attacks.
• Thermo Fisher introduced the MassARRAY® System in 2023, which combines various cardiac biomarkers to provide thorough diagnostics for heart disease.

Key Players:

• Abbott Laboratories
• Becton, Dickinson and Company
• Luminex Corporation
• Roche Diagnostics
• PerkinElmer, Inc.
• Bio-Rad Laboratories, Inc.
• bioMérieux SA
• Fujirebio
• Beckman Coulter
• ACON Laboratories, Inc.
• Ortho Clinical Diagnostics
• Siemens Healthineers
• Randox Laboratories Ltd.
• Trinity Biotech
• Thermo Fisher Scientific Inc.
• Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)

Regional Analysis

Cardiac Biomarkers Market is segmented based on regional analysis into five key regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. The North American region is anticipated to dominate the Cardiac Biomarkers Market as the region area has a robust healthcare system with advanced diagnostic facilities and widespread use of cardiac biomarkers. Also, there is a high occurrence of cardiovascular diseases in the area, leading to a need for efficient diagnostic equipment. Many top companies in the cardiac biomarkers sector are based in North America, helping to drive market expansion. Furthermore, the investment in medical research and development in this region leads to innovation in biomarker technologies, with support from a regulatory environment that helps approve and implement new diagnostic advancements.

Source: Fatpos Global

Impact of COVID-19 on the Cardiac Biomarkers Market

COVID-19 pandemic had a dual impact on the Cardiac Biomarkers Market. Initially, the pandemic led to interruptions in the supply chain, impacting the manufacturing and distribution of cardiac biomarker testing kits and reagents. Testing materials shortages and logistic delays affected the availability of these tests, causing challenges for healthcare providers. However, the pandemic highlighted the heart-related issues linked to severe COVID-19 cases, like myocarditis and acute coronary syndrome, leading to an increased need for cardiac biomarkers for diagnosis and treatment. The pandemic rapidly boosted the utilization of telemedicine and remote monitoring, which also included cardiac biomarker tests conducted at home. This resulted in fresh concepts in remote diagnostics and broadened the market for at-home testing and telehealth services. Furthermore, the pandemic accelerated the investigation into the connection between cardiac biomarkers and COVID-19, leading to new findings and possible advancements in biomarker creation.  

Cardiac Biomarkers Market is further segmented by region into:

• North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
• Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
• Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
• Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA

Cardiac Biomarkers Market Scope and Segments:

Frequently Asked Questions (FAQ):